Biocon Ltd
NSE: BIOCON BSE: 532523
₹369.75
(-0.68)%
Wed, 04 Feb 2026, 09:12 am
Market Cap600.21B
PE Ratio93.12
Dividend0.13
Health Technology
Pharmaceuticals: Major
24.5KAnalysis
dividend
- Biocon is not paying a notable dividend for India, therefore no need to check if the payments are increasing.
- No need to calculate the sustainability of Biocon's dividends as it is not paying a notable one for India.
- No need to calculate the sustainability of Biocon's dividends in 3 years as they are not expected to pay a notable one for India.
- Biocon is not paying a notable dividend for India, therefore no need to check if the payments are stable.
- Biocon's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Biocon's dividend is below the markets top 25% of dividend payers in India (3.08%).
future
- Cash flow for Biocon is expected to increase by more than 50% in 2 years time.
- Biocon's earnings are expected to grow significantly at over 20% yearly.
- Biocon's earnings growth is expected to exceed the India market average.
- Biocon's earnings growth is expected to exceed the low risk savings rate of 7.2%.
- Biocon's earnings are expected to exceed the low risk growth rate next year.
- Biocon's earnings are expected to increase by more than the low risk growth rate in 3 years time.
- Biocon's net income is expected to increase by more than 50% in 2 years time.
- Biocon is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
- Performance (ROE) is expected to be above the current IN Biotechs industry average.
- An improvement in Biocon's performance (ROE) is expected over the next 3 years.
- Biocon's revenue is expected to increase by more than 50% in 2 years time.
- Biocon's revenue growth is expected to exceed the India market average.
- Biocon's revenue is expected to grow by 19.4% yearly, however this is not considered high growth (20% yearly).
health
- Biocon is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Biocon is profitable, therefore cash runway is not a concern.
- Biocon is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (67.9%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 2.8x debt.
- Biocon's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (32.6% vs 25.6% today).
- Interest payments on debt are well covered by earnings (EBIT is 16.2x coverage).
- Biocon's level of debt (25.6%) compared to net worth is satisfactory (less than 40%).
- High level of physical assets or inventory.
management
- The tenure for the Biocon board of directors is about average.
- Siddharth's remuneration is lower than average for companies of similar size in India.
- Siddharth's compensation has increased by more than 20% in the past year whilst earnings fell less than 20%.
- Biocon individual insiders have only sold shares in the past 3 months.
- The average tenure for the Biocon management team is less than 2 years, this suggests a new team.
misc
- Biocon has significant price volatility in the past 3 months.
past
- Biocon's year on year earnings growth rate has been positive over the past 5 years.
- Biocon has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
- Biocon's 1-year earnings growth is negative, it can't be compared to the 5-year average.
- Biocon used its assets less efficiently than the IN Biotechs industry average last year based on Return on Assets.
- Biocon has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- Biocon's 1-year earnings growth is negative, it can't be compared to the Asia Biotechs industry average.
value
- 532523 outperformed the Biotechs industry which returned 53.2% over the past year.
- 532523 outperformed the Market in India which returned -14.5% over the past year.
- BSE:532523 is up 17.3% along with the Biotechs industry (18.2%) over the past month.
- BSE:532523 is up 17.3% outperforming the market in India which returned 8% over the past month.
- Biocon's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Biocon's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- Biocon is overvalued based on assets compared to the IN Biotechs industry average.
- Biocon is poor value based on expected growth next year.
- Biocon is overvalued based on earnings compared to the IN Biotechs industry average.
- Biocon is overvalued based on earnings compared to the India market.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800